Investing.com - Avid Bioservices (NASDAQ: CDMO) reported third quarter EPS of $0.01, $0.02 better than the analyst estimate of $-0.01. Revenue for the quarter came in at $38M versus the consensus estimate of $36.32M.
Guidance
Avid Bioservices sees FY 2023 revenue of $145.00M-$150.00M versus the analyst consensus of $146.00M.
Avid Bioservices's stock price closed at $13.82. It is down -3.36% in the last 3 months and down -26.92% in the last 12 months.
Avid Bioservices saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Avid Bioservices's stock price’s past reactions to earnings here.
According to InvestingPro, Avid Bioservices's Financial Health score is "good performance".
Check out Avid Bioservices's recent earnings performance, and Avid Bioservices's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar